Nektar Therapeutics Achieves Positive Phase 2b Study Results

Nektar Therapeutics shares are trading higher after the company announced its REZOLVE-AD Phase 2b study of rezpegaldesleukin met primary and key secondary endpoints, showing potential as a first-in-class immune modulator for atopic dermatitis.